285 related articles for article (PubMed ID: 30191850)
1. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
Pe M; Dorme L; Coens C; Basch E; Calvert M; Campbell A; Cleeland C; Cocks K; Collette L; Dirven L; Dueck AC; Devlin N; Flechtner HH; Gotay C; Griebsch I; Groenvold M; King M; Koller M; Malone DC; Martinelli F; Mitchell SA; Musoro JZ; Oliver K; Piault-Louis E; Piccart M; Pimentel FL; Quinten C; Reijneveld JC; Sloan J; Velikova G; Bottomley A;
Lancet Oncol; 2018 Sep; 19(9):e459-e469. PubMed ID: 30191850
[TBL] [Abstract][Full Text] [Related]
2. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review.
Chakraborty R; Cannella L; Cottone F; Efficace F
Lancet Haematol; 2020 Dec; 7(12):e892-e901. PubMed ID: 33242446
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review.
Sparano F; Aaronson NK; Sprangers MAG; Fayers P; Pusic A; Kieffer JM; Cottone F; Rees J; Pezold M; Anota A; Charton E; Vignetti M; Wan C; Blazeby J; Efficace F
BMJ Support Palliat Care; 2019 Dec; 9(4):451-463. PubMed ID: 31719051
[TBL] [Abstract][Full Text] [Related]
4. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.
Bottomley A; Pe M; Sloan J; Basch E; Bonnetain F; Calvert M; Campbell A; Cleeland C; Cocks K; Collette L; Dueck AC; Devlin N; Flechtner HH; Gotay C; Greimel E; Griebsch I; Groenvold M; Hamel JF; King M; Kluetz PG; Koller M; Malone DC; Martinelli F; Mitchell SA; Moinpour CM; Musoro JZ; O'Connor D; Oliver K; Piault-Louis E; Piccart M; Pimentel FL; Quinten C; Reijneveld JC; Schürmann C; Smith AW; Soltys KM; Sridhara R; Taphoorn MJB; Velikova G; Coens C
Clin Trials; 2018 Dec; 15(6):624-630. PubMed ID: 30141714
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.
Mercieca-Bebber RL; Perreca A; King M; Macann A; Whale K; Soldati S; Jacobs M; Efficace F
Eur J Cancer; 2016 Mar; 56():144-161. PubMed ID: 26851406
[TBL] [Abstract][Full Text] [Related]
6. The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature.
Turner-Bowker DM; Hao Y; Foley C; Galipeau N; Mazar I; Krohe M; Globe D; Shields AL
Curr Med Res Opin; 2016 Oct; 32(10):1709-17. PubMed ID: 27331272
[TBL] [Abstract][Full Text] [Related]
7. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
Coens C; Pe M; Dueck AC; Sloan J; Basch E; Calvert M; Campbell A; Cleeland C; Cocks K; Collette L; Devlin N; Dorme L; Flechtner HH; Gotay C; Griebsch I; Groenvold M; King M; Kluetz PG; Koller M; Malone DC; Martinelli F; Mitchell SA; Musoro JZ; O'Connor D; Oliver K; Piault-Louis E; Piccart M; Quinten C; Reijneveld JC; Schürmann C; Smith AW; Soltys KM; Taphoorn MJB; Velikova G; Bottomley A;
Lancet Oncol; 2020 Feb; 21(2):e83-e96. PubMed ID: 32007209
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.
Van Hemelrijck M; Sparano F; Josephs D; Sprangers M; Cottone F; Efficace F
BMC Urol; 2019 Sep; 19(1):86. PubMed ID: 31521149
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.
Ibrahim F; Tom BD; Scott DL; Prevost AT
Trials; 2016 Jun; 17(1):272. PubMed ID: 27255212
[TBL] [Abstract][Full Text] [Related]
10. Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019.
Efficace F; Giesinger JM; Cella D; Cottone F; Sparano F; Vignetti M; Aaronson NK
Value Health; 2021 Dec; 24(12):1715-1719. PubMed ID: 34838268
[TBL] [Abstract][Full Text] [Related]
11. Information about missing patient-reported outcome data in breast cancer trials is frequently not documented: a scoping review.
Krepper D; Giesinger JM; Dirven L; Efficace F; Martini C; Thurner AMM; Al-Naesan I; Gross F; Sztankay MJ
J Clin Epidemiol; 2023 Oct; 162():1-9. PubMed ID: 37517504
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.
Stefanovic S; Wallwiener M; Karic U; Domschke C; Katic L; Taran FA; Pesic A; Hartkopf A; Hadji P; Teufel M; Schuetz F; Sohn C; Fasching P; Schneeweiss A; Brucker S
Support Care Cancer; 2017 Feb; 25(2):549-558. PubMed ID: 27747478
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review.
Howard AF; Goddard K; Rassekh SR; Samargandi OA; Hasan H
Trials; 2018 Oct; 19(1):539. PubMed ID: 30290839
[TBL] [Abstract][Full Text] [Related]
14. Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review.
Mizusawa J; Ogawa G; Terada M; Ishiki H; Kikawa Y; Kiyota N
Cureus; 2024 May; 16(5):e60804. PubMed ID: 38910767
[TBL] [Abstract][Full Text] [Related]
15. Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review.
Weingärtner V; Dargatz N; Weber C; Mueller D; Stock S; Voltz R; Gaertner J
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):821-9. PubMed ID: 26959869
[TBL] [Abstract][Full Text] [Related]
16. Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.
Rombach I; Gray AM; Jenkinson C; Murray DW; Rivero-Arias O
BMC Med Res Methodol; 2018 Aug; 18(1):87. PubMed ID: 30153796
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
Fossati R; Confalonieri C; Mosconi P; Pistotti V; Apolone G
Breast Cancer Res Treat; 2004 Oct; 87(3):233-43. PubMed ID: 15528966
[TBL] [Abstract][Full Text] [Related]
18. Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.
Mouillet G; Efficace F; Thiery-Vuillemin A; Charton E; Van Hemelrijck M; Sparano F; Anota A
Cancer Med; 2020 Oct; 9(20):7363-7374. PubMed ID: 32846465
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive review of statistical methods for analysing patient-reported outcomes (PROs) used as primary outcomes in randomised controlled trials (RCTs) published by the UK's
Qian Y; Walters SJ; Jacques R; Flight L
BMJ Open; 2021 Sep; 11(9):e051673. PubMed ID: 34489292
[TBL] [Abstract][Full Text] [Related]
20. No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals.
Gabler NB; Duan N; Raneses E; Suttner L; Ciarametaro M; Cooney E; Dubois RW; Halpern SD; Kravitz RL
Trials; 2016 Jul; 17(1):320. PubMed ID: 27423688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
